CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year
CNSP•Strategy update
A strategy shift announced in March 2026 targets new development-stage assets, while exploring out-licensing of legacy TPI 287 and Berubicin.
Income and cash position
Interest income more than doubled to $116,000, lifting other income to $112,000; cash totaled $20 million at quarter-end.
Quarterly loss widens as expenses rise
CNS Pharmaceuticals posted a net loss of $2.59 million for the quarter ended June 30, 2026, widening 9% year over year.
Operating loss widened 12.1% to $2.7 million as total operating expenses climbed 12.1% to $2.7 million.
General and administrative costs rose 20.7% to $1.5 million; research and development spending edged up 2.9% to $1.2 million.
